Heart Drug Lowers Lp(a) but Fails to Cut Cardiovascular Risk, Casting Doubt on Rivals
Biotech·November 9, 2026
The full results from a closely watched cardiovascular trial are in, and they are a setback for the drug's developers. The compound did what it was designed to do at the biochemical level: it lowered lipoprotein(a), usually written Lp(a), a cholesterol-carrying particle that genetics links to heart attacks and strokes. But the lower readings did not translate into any cardiovascular benefit for patients in the study.
That gap is the core problem. Lp(a) levels are largely set by genes and respond poorly to standard cholesterol drugs, which is why it has drawn so much attention as a target. A number of companies have been building therapies aimed at the same particle, and many of their plans assume that pushing Lp(a) down will prevent heart events. A clean miss on outcomes forces a harder question: is the biomarker the right target, or does a drug need to do more than move the number?
For rivals, the read-through is uncomfortable. Their programs rest on similar reasoning, and their timelines and valuations often depend on that link holding up. Analysts will be checking whether competing trials measure the same endpoints, and whether differences in dose, potency or patient selection could explain the outcome. The result does not automatically sink any other program, but it raises the bar for proof.
Investors and clinicians will be watching how the sponsor explains the findings in detail, and whether regulators or other drugmakers offer their own interpretation. For now, the lesson is a simple one: lowering Lp(a) is not the same as showing it prevents heart attacks.
Reporting based on an external source.